The current invention provides a prophylactic HPV vaccine. Immunization against peptides from the HPV L2 protein gives a robust immune reaction that provides cross-protection against a variety of other high-risk HPV strains. Tha vaccine is based on a thioredoxin-L2 construct and can be produced in standard E. coli bacteria, which makes a cost-effective production feasible.
Rocaglamide makes tumour cells more susceptible to anti-proliferative agents while leaving normal cells unaffected. This allows dose reduction of apoptosis inducers and in parallel improves dramatically the patient’s condition during cancer treatment.
The invention provides a needle-based navigation system for CT-guided radiofrequency ablation of the liver. The key facts are: (1) Precise intervention and navigation aid for soft tissue surgery; (2) Real-time observation and supervision; (3) Inexpensive hardware/software equipment
Radiotherapy is a well-established method to treat certain tumor types in particular brain tumors. For fixation of the patient's head a “mask” is used, with is connected to the plate where the patient is located on. The novel technology describes a non-invasive procedure, where the patient mask is produced by rapid prototyping based on CT/MR data.
Specific inhibition of histone deacetylases by BMP4 efficiently restores aberrant signaling pathways and biological features in experimental neuroblastoma at nanomolar concentration without unfavorably targeting untransformed cells. In addition, recombinant manufactured BMP4 is already established for other indications (osteoporosis and type 2 diabetes), which should support the approval for this new indication.
The peptides identified by our inventors block the intracellular activity of the HPV16 E6 protein and thus increase sensitivity of tumor cells towards apoptosis. This effect is highly specific for HPV16-containing tumor cells.
Since cell culture contamination cannot be totally avoided, regular testing is a key factor for good cell culture management. The present invention provides means and methods to simultaneously detect up to 35 viral, microbial and inter-species contaminations. It facilitates sensitive and reliable determination of cell line purity. The technology is based on multiplex PCR and Luminex detection. Especially production units can profit from this cost-effective high-throughput method.
Method for the enrichment of diagnostic target molecules based on CD24 positive exosome purification, enabling the development of mainly cancer or fetal diagnostics and reducing false negative test results due to diluted diagnostic target molecules.
Metformin is a well-known anti-diabetic drug. The current technology offers the opportunity to use Metformin, as second medical use, for the treatment of multiple sclerosis and graft-versus-host disease.
DKFZ together with Technical University of Denmark (DTU) developed an analogue of Griseofulvin as a compound for cancer treatment, which selectively targets cancer cells only.
L1 is overexpressed in highly malignant carcinomas and human ovarian tumors. The antibody 9.3 has improved anti-tumor capacities by inhibit tumor growth and invasion of tumor cells. Antibody can be also used to determine the L1 level in a patient.
“Ready to use kit” for simultaneous quantitative detection of up to 51 HPV genotypes. Kit contains internal quality and performance controls and allows identification of cervical abnormalities by predefined high viral load cutoffs.
Quadscanner for High Resolution Scanning Microscopes and Array Readers. The key facts are: (1) Fast, adaptive optical scanning device; (2) Completely free positioning of the scanning mirrors regarding the conjugated back focal plane; (3) Calibration with 4 galvanometers; (4) Application in high resolution microscopes (fluorescence, Raman, STED, localization), but also in Array Readers.
The technology specifies a novel device which allows to stabilize images of optical microscopes with high resolutions against externally induced oscillations and drift effects. In particular for optical microscopes, which achieve a higher resolution, it is important to ensure a high mechanical stability of the structure of microscope for a good image quality. It improves the performance of instruments such as laser scanners, fluorescence microscopes, Raman systems, STED- or localization-microscopes.
Optical techniques, such as bioluminescence and fluorescence, are emerging as powerful new modalities for molecular imaging in disease and therapy. Combining innovative molecular biology and chemistry, researchers have developed optical methods for imaging a variety of cellular and molecular processes in vivo, including protein interactions, protein degradation, and protease activity. DKFZ developed an optical imaging detector regarding fluorescence and bioluminescence for small animal imaging, which is compatible for magnetic resonance imaging (MRI). This technology provides the possibility to study simultaneously tracer/marker kinetics of optical (OT) as well as NMR induced signals.
DKFZ developed an optical imaging detector (25 mm x 100 mm photon sensor) for fluorescence and bioluminescence in small animal imaging, which is compatible for magnetic resonance imaging (MRI), computer tomography (CT), positron electron tomography (PET) and Single-photon emission computed tomography (SPECT). The instrument has been evaluated regarding ist optical performance including radiation durability using various phantoms and measurement setups and was successfully used in a number of preclinical studies such as simultaneous positron (18F-FDG, 68Ga-RGD) – bioluminescence (PC-3-hVEGF-Luc) imaging of reporter gene expression and receptor targeting in mice or simultaneous imaging of fluorescent XenoLight-RediJect-2-DG-750 and radiolabeled FDG probes.
Rückmeldung
